1. Home
  2. SAGE vs HPP Comparison

SAGE vs HPP Comparison

Compare SAGE & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • HPP
  • Stock Information
  • Founded
  • SAGE 2010
  • HPP 2009
  • Country
  • SAGE United States
  • HPP United States
  • Employees
  • SAGE N/A
  • HPP N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • HPP Real Estate
  • Sector
  • SAGE Health Care
  • HPP Finance
  • Exchange
  • SAGE Nasdaq
  • HPP Nasdaq
  • Market Cap
  • SAGE 462.2M
  • HPP 481.6M
  • IPO Year
  • SAGE 2014
  • HPP 2010
  • Fundamental
  • Price
  • SAGE $5.61
  • HPP $2.94
  • Analyst Decision
  • SAGE Hold
  • HPP Hold
  • Analyst Count
  • SAGE 19
  • HPP 11
  • Target Price
  • SAGE $11.53
  • HPP $5.95
  • AVG Volume (30 Days)
  • SAGE 1.1M
  • HPP 6.6M
  • Earning Date
  • SAGE 02-12-2025
  • HPP 02-10-2025
  • Dividend Yield
  • SAGE N/A
  • HPP 3.41%
  • EPS Growth
  • SAGE N/A
  • HPP N/A
  • EPS
  • SAGE N/A
  • HPP N/A
  • Revenue
  • SAGE $106,399,000.00
  • HPP $847,713,000.00
  • Revenue This Year
  • SAGE N/A
  • HPP N/A
  • Revenue Next Year
  • SAGE $122.78
  • HPP N/A
  • P/E Ratio
  • SAGE N/A
  • HPP N/A
  • Revenue Growth
  • SAGE 837.60
  • HPP N/A
  • 52 Week Low
  • SAGE $4.62
  • HPP $2.39
  • 52 Week High
  • SAGE $28.26
  • HPP $9.86
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 50.27
  • HPP 37.31
  • Support Level
  • SAGE $4.94
  • HPP $2.39
  • Resistance Level
  • SAGE $5.91
  • HPP $3.33
  • Average True Range (ATR)
  • SAGE 0.36
  • HPP 0.30
  • MACD
  • SAGE 0.02
  • HPP -0.05
  • Stochastic Oscillator
  • SAGE 69.07
  • HPP 36.82

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

Share on Social Networks: